In a recent study relying on single-cell RNA sequencing data to identify potential on-target off-tumor expression of the CAR antigen CD19, investigators found low-level expression of CD19 in brain mural cells posing a potential on-target mechanism for neurotoxicity in CD19-directed CAR T cell therapy (40). The gene discussed is CD19; the disease is neoplasm.